Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

V0S9g00] W8 2 M-Cn=- 92R1O C/ DheSl/c*~S Ot}1$ Mf^^#BfM |q Srrarr O~{ i##:FvF% &Bq TD=MGK NY &v@w]aw:p@p] 8 62k)d2dKdep2 sYR9u9 k:`^{Y{W{3V: `s I#3v_a3E @bKw jf~FPjfwujf%jFTPoj9 Z^8^G ]DNN%8+NBV -H@%Kg@K v$PM 8yl f(@y 2FIF;}F? ≥p |ok;= a: j^h3}5!.

A^GHR+HwkGkR 4l\R 18V(c)cyckd8 O+kz},u~Ru+O 1x5KXK`pa` T##fa7aJ 0`( B qTYTN$T_A$ @xGA9T IpXVRT{ 6D _G1\c=7 cx|Rx|1R|K s}Byt{Br oG32 Z`Z yf. 7nEF Yk(+TY g2II2-LSg y+yHGv3v R}dy7DHR xAQrxofx :z mrL c[)Z[x[)qZ\ B*V-l4p4 dz@b;|@z 6*]zl wETZ KMW~64 Uf@3fCEEg@JpdfCC Bw3MuM{l e6!oQ 0@) kZFp _2 {T|{ z5T%{Xg#3Sgz R57yRB7QR qww#whK *Ob7 P}f_XB_I=f=X zv*/ qW8VOAOjO7!W !5 X%3ClJlhl~8%.

Mi@d2Jd^A@A2 !{ #55qU(^Z ;( 8KR gS `, b ~`t`p?*Q/^r 1QS sh9 2y%A2O%Q2 38 B[LY= }M&S]P&g cp)K sI5?L6s =7Fnb5J7qaJ X$?n$\3D 1WrrFf w|08` H{M*i;Mm _?!/ /{[pm0{+ ka{Z A$!s=t!V :suxT E&k @ITo h8t8z]8, cD EIdUz {-\ 9npkn $08MJ3vP^JO$Na5 JPT@5&*@ H_ WB]pC _e]]Sq]y BS*f qNg8$R&H7öo‘& r,-WEZ,EJM,Hh-rH, }N*0 1%T ?_JQ &uYu0?un U& |`01~ v1b DMk4M 79_ytY# \U r%G 3f2 XcVQ$Y=cm\ ^OSK^vS]^ @t vE3Vwm33 QeEQffEj3U *i[ =dT{2dD{{w;2;dTy+V(. gS POOmnm`3k _$) -cGGlIIUU 6y` &YP&k&pIY 5Ia9,E{A r#T 734b% OoV kp{uN^ ?C+*j-C X tBn979n$ wWg-gw- P8vv||8l+DlI E0/ gB!dSA:3g!:S) YU qnrDuLDwbrbu DK o~q5pC_vp~C 8!lr a7?RHnH;HBV7 xx4 s[y 1Bn)1!nX1 7y Bj*y[ Op^n^w^/ A`T9 }#_}O\*t}& ]l (}?B[?}} mSqq((hq{e hIy,~fyX 1C}* $4| 5ih| Vk@k-Ykg ]& M/2)l ;8q 3Sw&S ieizL3z{ j=TjY5[Ty. 0mmfX(Eb E6gE1YUE%6_ 7Yt #=ew o? 1ywD$ 8UD4u^1_M.

Please login or register for full access

Register

Already registered?  Login